Specific hay fever therapy has long been based on the inoculation of pollen extracts, a regimen whose efficacy is not definitely established and whose mode of action is poorly understood (1) . At the clinical level, injection of the culpable antigens in subreactive amounts is often followed by symptomatic improvement and diminished allergic responses of the mucous membranes and skin (1) (2) (3) (4) . Immunologically, these changes coincide with an increased production of blocking and hemagglutinating antibodies and, probably, with a diminution in the skin-sensitizing capacity of the serum (5) (6) (7) (8) . Despite these findings, efforts to establish a causal relationship between the parenteral injection of antigen, the immune response, and symptomatic relief -have met with considerable difficulty (9, 10) . The major problems have been the lack of accurate and valid procedures for assessing the degree of sensitivity to the pollen antigens and for characterizing the patient's immune response in terms of his clinical status. of histamine from human leukocytes by ragweed pollen antigen (11) (12) (13) (14) . These procedures appear suitable for the study of human allergic disease in that they mimic the in vivo situation and permit a quantitative evaluation of several facets of the allergic response, namely: 1) the capacity of leukocytes from a ragweed-sensitive donor to release histamine on interaction with physiologically active quantities of a purified pollen antigen (11, 12) ; and 2) the ability of serum from an allergic donor to react with antigen in the fluid phase, thereby diminishing the anaphylactic release of histamine from the leukocytes (13, 14) .
These two procedures have now been applied to a combined clinical and laboratory undertaking designed to evaluate the effects of parenteral immunization on the course of human ragweed allergy. VanArsdel and Middleton have previously demonstrated a decrease in histamine release from the whole blood of patients undergoing specific hyposensitization (15) [see also Spain, Strauss, and Neumann (16) ]. In the present study a washed suspension of leukocytes has been used, rather than whole blood, to permit an independent evaluation of both humoral and cellular factors. Furthermore, the development of a more accurate system for assessing patient symptomatology (17) and the availability of a single highly purified antigen from ragweed pollen (18, 19) have significantly facilitated comparisons of laboratory and clinical observations. Methods Selection of patients. The patients selected for this study were drawn from a larger group undergoing a therapeutic trial designed to compare the clinical efficacy of crude ragweed pollen extract with its highly purified derivative, antigen E, and a saline placebo. Each subject presented a history of hay fever symptoms restricted, 1126 with few exceptions, to the season of ragweed pollination. The leukocytes of 56 patients were assayed for their ability to release histamine on contact with antigen.
Forty-one responded adequately. The remaining 15 were rejected for the following reasons: In two cases, histamine was not released at the antigen level tested. The leukocytes of five subjects released less than 50% of their available histamine, and in five other cases untowardly high blanks were observed when the cells were incubated with serum from nonallergic donors in the absence of antigen (cf. 13) . In three cases the leukocyte histamine levels were too low for assay.
The 41 patients were divided into three groups. Eleven subjects had received antigen E previously, and this therapy was continued. The remaining 30 patients were randomly divided between the placebo and crude ragweed treatment groups. For various technical reasons a complete set of data was not obtained from all donors.
Desensitization treatment. The crude ragweed extract was obtained in concentrated form1 and contained 10,000 protein nitrogen units (100 gg protein N) per ml.
The antigen E content of this material was 38 ,ug per ml (20) . Antigen E was furnished as Fraction IV C by Dr. T. P. King, who reported that 99% of this material was antigen E (18, 19) . Antigen E is 17.1 ± 0.3% nitrogen by analysis (19) . All patients received 15 injections at weekly intervals from May 6 to August 12, 1964 . The physician administering the injections was aware of the individual's therapeutic regimen, but the patient was not informed of the nature of the injected material. The first injection consisted of 0.002 4g (0.0003 Iug protein N) for the patients treated with antigen E and 0.001 yg protein N for the patients treated with whole ragweed extract. These doses were doubled each week provided the previous injection had produced no reaction. When a reaction did occur, the dose was maintained at the previous level; the quantity was reduced after severe reactions. Of the 15 patients receiving whole ragweed extract, only two completed the projected course of doubling doses for 15 injections. In the others, dosage was limited by local pain, itching, and swelling at the site of injection. Four patients showed mild to moderate systemic reactions in the form of hives. The total preseasonal dose for this group ranged from 0.39 to 28.8 /g protein N, containing 0.15 to 11 jug antigen E (0.026 to 1.84 ltg protein N). Of the ten patients receiving antigen E, five completed the projected course; one of these received an additional injection inadvertently. In four of the patients who did not complete the projected course, the dosage was limited by local reactions, mostly of the immediate wheal and erythema type. The fifth patient had a mild systemic reaction. The total preseasonal dose in the group treated with antigen E ranged from 4.0 to 61.7 /Ag (0.7 to 11.2 ,ug protein N).
Evaluation of hay fever symptoms. A daily symptom diary card 2 Pollen counts. Quantitative ragweed pollen counts were obtained from roto-slide samplers placed at several locations in the Baltimore area. 4 Histamine release procedure. The methods used for the estimation of histamine release from washed leukocyte suspensions and for measurements of antigen-neutralizing capacity in sera from allergic donors have previously been described in detail (11, 13, 14) . They may be briefly summarized as follows: Blood was drawn by venipuncture, and the leukocytes were isolated, washed and suspended in a Tris-buffered solution containing optimal levels of calcium and magnesium, as well as 0.03% human serum albumin (Tris-ACM). The final concentration of leukocytes was 3.75 X 106 per ml, as estimated with a model A Coulter counter.
Antigen. Antigen E (provided as Fraction IV) was stored in the frozen state as previously described (11) . presence of a large excess of antibody, so that a con-50NHS 1.1 stant percentage, rather than a constant quantity, of the added antigen is rendered unreactive. In the ragweed system this phenomenon is observed over the entire range e1s0ondSerumLML of antigen concentrations utilized, that is, from 10' to 10' iug of protein per ml (14) . but lacking ragweed antigen. When this "spontaneous" release exceeded 10%o, the experiment was discarded.
Normal human serum (NHS
Allergic human serum (AHS). Whenever blood was drawn for leukocyte isolation, an additional quantity was obtained to provide serum for antigen-neutralizing capacity titrations. The serum was removed within 2 hours after drawing the blood and was not heat inactivated. The antibody level was titrated on the day the serum was obtained.
Assay for antigen-neutralizing capacity. Since human serum from nonallergic donors may enhance the release of histamine, estimates of antigen-neutralizing capacity in AHS were always compared with a NHS control (14) . Preliminary antigen dose-response curves were established for the cells of each donor so that subsequent titrations might be in the range of partial response. This was necessary because the dose response curves of different cell populations vary over a 10,000-fold range (11) . The use of inappropriately high levels of antigen may therefore provide data in the insensitive "plateau" region of the curve, or even in the region of inhibition due to antigen excess. Appropriate dilutions of ragweed antigen were mixed with samples of pooled NHS or autologous AHS, each at a final concentration of 10%o. After incubation for 60 minutes at either 25°0 or 370 C (14), the antigen-serum mixtures were transferred to a 40 C bath. One ml of a standardized suspension of the patient's cells was then added to each reaction tube, which was incubated at 37' C for 60 minutes. The tubes were centrifuged and the supernates assayed for released histamine by a modification (11) of the fluorometric method of Shore, Burkhalter, and Cohn (21) . A typical experiment, yielding two dose-response curves, is shown in Figure 1 . The displacement of the line describing the AHS titration relative to that of the NHS titration provides a measure of the antibody activity in the allergic serum. The amount of antigen required for 50% histamine release in AHS divided by the amount necessary for the same percentage release in NHS yields the ratio, GO(AHS/NHS). This ratio describes the Results I) Titrations for antigen-neutralizing capacity A) Sera of untreated patients. Before initiating therapy we determined the level of antigen-neutralizing capacity (ANC) in 80 sera obtained from 32 patients who had never received parenteral injections of ragweed extract for diagnostic or therapeutic purposes. The results of these analyses are given in Figure 2 . ratio observed in this normal group was 1.25, indicating that, within experimental error, there was no antigen binding by these normal sera. In contrast, the sera of all ragweed-sensitive patients tested thus far exhibit ragweed-neutralizing activity. B) Sera of placebo-treated patients. The antibody activity levels in the sera of patients in the placebo and crude ragweed extract groups, both previously untreated, were similar before therapy (Table I ). The G50(AHS/NHS) values for the placebo group were essentially constant throughout the period of study, with a tendency towards a slight decline during the last 4 months (Table I, Figure 3 , solid circles).
C) Sera of patients treated with crude ragweed extracts. These sera showed a moderate increase in ANC for antigen E (Table I, Figure 3 ). The average values rose from 3.2 before treatment to 8.3 (Table I) , and the sera of two individuals exceeded a value of 10 ( Figure 3 ). This modest response may reflect the fact that only small quantities of antigen E are present in crude extracts. Although the patients received 0.39 to 28.8 ug protein N of the crude extract, the amount of antigen E contained therein was but 0.15 to 11 ,ug protein (0.026 to 1.84 jug protein N). All the ANC assays were carried out with antigen E so that antibodies to the remaining antigenic constituents of ragweed would not have been detected. There was no apparent correlation between the quantity of antigen administered and the maximal serum antibody levels. Only half of the group, however, manifested a rise in antibody levels greater than those in the sera from nontreated allergic donors. During the subsequent period of treatment, in 1964, the sera of all individuals treated with antigen E developed increased antigen-neutralizing activity. The results of successive titrations with the sera of six individuals representing the entire range of results are plotted in Figure 4 . The pattern of response in these individuals differs from that of subjects treated with crude extract mainly with respect to the magnitude of the antigen-neutralizing activity (cf. Figure 3) . A logarithmic ordinate was used in Figure 4 to include the entire range of G50(AHS/NHS) values. The rise in antibody activity occurred from May to September. When desensitization was discontinued in August, the neutralizing activity in all sera continued to rise for a month or two, and then fell rather rapidly, as was also noted in the crude ragweed group.
The data compiled in Table II show that there was a significant correlation between the magnitude of the immunizing dose and the maximal antibody level (p < 0.01). II) Changes in cell sensitivity after therapeutic immunization Before the onset of desensitization therapy the cell sensitivities of the three treatment groups were quite similar. The median value and range of the antigen concentrations required for 50%o histamine release in NHS were 48 X 10-6 (9 to 500 X 10-6), 28 X 10-6 (5 to 600 X 10-6), and 56 x 10-6 (5 to 320 x 10-6) ,ug per ml, for the placebo-, antigen E-, and crude ragweed-treated groups, respectively.
The change in leukocyte reactivity for each subject as a consequence of specific therapy is depicted in Figure 5 . Each point in the graph represents the logarithm of the ratio between the mean cell sensitivity obtained in two assays before the onset of therapy and that found in two titrations performed during and immediately after the ragweed season, i.e., at the conclusion of therapy. The quantity of antigen required for 50%o histamine release increased in six of the eleven subjects in the placebo group (e.g., the cells became less sensitive) and decreased in five. Thus, for the group as a whole there was little change in the amount of antigen required to yield a 50%o response, the average value of the ratios before and after the ragweed season being 0.041 ± 0.35. The results for the crude ragweed group as a whole are quite similar. In the antigen E-treated group, on the other hand, the leukocytes of nine individuals required more antigen after treatment, whereas in only two was less antigen required. (11) . Such individuals were not included in this study.
III) Clinical results
The severity of the clinical illness, as measured by the average daily symptom score, correlated well with natural exposure to pollen as measured by quantitative ragweed pollen counts ( Figure 6 ). Symptoms tended to be somewhat greater in relation to the pollen count late in the ragweed season, an observation made previously with respect to daily symptom evaluation (17) .
The average daily symptom scores for the entire ragweed season were slightly lower for the two treated groups than for the placebo group (Table III) , the differences being due largely to the divergence in scores during the height of pollen exposure ( Figure 6 ). Physician evaluation scores showed the same trend (Table III) (23) . In addition, the amounts of crude extract employed in this study were smaller than those that yielded successful results in two other controlled clinical studies (23, 24) , although they were similar to those used in the allergy clinic of this institution. The dose of antigen E that might be required to produce a good therapeutic result is still unknown. However, a few of the patients receiving antigen E may have experienced clinical improvement, as discussed below.
IV) Laboratory-clinical correlations
The failure to find significant differences in the clinical status of the placebo group as compared to the two immunized groups obviously limits the possible correlations between laboratory results and the effects of treatment. A significant relationship did, however, emerge in comparisons of the in vitro reactivity of a patient's cells to antigen E and the severity of his symptoms. Figure 7 links the cell sensitivity, i.e., the G50NHS, determined before the ragweed season, with the symptom scores as evaluated by the patient (left) and by the physician (right), for the 24 patients of the placebo-and crude ragweed-treated groups. Those individuals whose cells were most sensitive (i.e., their cells required the least antigen for 50%o histamine release) generally experienced the most severe symptoms. The Spearman rank correlation coefficient between cell sensitivity and severity of symptoms was higher (0.77) in terms of the patients' daily scores than in terms of the physician's scores (0.59). Both methods of evaluation provide a statistically significant correlation (p < 0.01). Since relatively small changes in individual cell sensitivity were observed over the period of this study ( Figure 5) , as compared to the range of cell sensitivities shown in Figure 7 , these correlations would obtain throughout the entire period of study. Those cell sensitivities determined before the ragweed season are reported in Figure 7 to illustrate the prognostic utility of this correlation.
When the placebo-and the crude ragweedtreated groups were considered separately, the correlation between cell sensitivity and symptom scores, as judged by either the patient or the doctor, was still significant. Each of the four correlations was at the p < 0.05 to 0.01 level. It follows therefore that an assay of cell sensitivity in an untreated individual has predictive value for the relative severity of hay fever symptoms likely to be experienced during the season of ragweed pollination.
For the group treated with antigen E, in contradistinction to the two other groups, the cell sensitivity did not predict the observed symptomatology. In this group were found the sera that showed the highest antigen-neutralizing activities, and it appears that the antibody level may have influenced the intensity of symptoms. This possibility is considered in Table IV , which lists the cell sensitivity of the donors in this group and, employing this value, an expected symptom score interpolated from Figure 7 (patient evaluation). Also recorded is the patient's maximal antibody level and, finally, his actual symptom score. It can be seen that in three patients the symptom scores expected from the cell sensitivity levels were attained (Ri, Wy, and St), and each of these donors developed only a minimal rise in antibody level [G50(AHS/NHS) = 11, 13, and 33, respectively]. On the other hand, five patients had fewer symptoms than expected (El, Ke, Ki, Ne, Yo), and these donors had the highest levels of antibody [G50(AHS/NHS) = 125, 120, 47, 1,000, 100, respectively. The remaining two donors had relatively insensitive cells and experienced more severe symptoms than predicted by their cell sensitivity. These results are compatible with the suggestion that high levels of circulating antianaphylactic antibody can influence the clinical response of allergic donors, but it will be necessary to-study a greater number of patients before this hypothesis is confirmed. trolled clinical situation involving desensitization therapy. We have studied the relationship between three different parameters: 1) the sensitivity of a donor's cells to the inciting antigen; 2) the level of antibody reactive with this antigen, as detected by its capacity to inhibit the allergic response; and 3) the intensity of the symptomatology manifested by the patient during the season of environmental exposure to the antigen. In each instance the response of patients under immunization with the offending antigen has been compared with that of controls who received only placebo injections.
Discussion
We showed earlier that allergic patients differ markedly in the quantity of antigen required for a 50%o release of histamine (11) . It may now be concluded that this in vitro measurement of sensitivity to specific antigen is closely correlated with the frequency and intensity of symptoms experienced by the cell donor ( Figure 7 ). This correlation attests to the validity of the present in vitro procedure as an experimental reaction system. Measurements of skin-sensitizing antibody (25) have also been shown to provide an index of patient symptomatology, but this procedure is a less precise prognostic tool than are the cell sensitivity studies reported here. Direct skin testing, on the other hand, has not been considered a useful index of the severity of the clinical condition (26, 27) .
The changes in cell sensitivity that resulted from treatment or from environmental exposure to ragweed antigen were quantitatively unimpressive, as the maximal change was less than ten- The sera of all ragweed-sensitive patients, including those of untreated individuals, contain allergen-binding antibodies, as shown by the data in Figure 2 . The level of this antibody activity did not change significantly as a result of environmental exposure to antigen during the ragweed season, but did increase after immunization (Tables I and II, Figures 3 and 4) . The increase was moderate in the group treated with crude ragweed, and in about half of these subjects the antibody levels were no higher than 1 SD above the average for the untreated group. As noted above, the inoculum for these individuals contained many ragweed pollen antigens, whereas only one was used in estimating the antibody response. In contrast, all individuals treated with antigen E responded with an increased level of antibody activity (Table  II, Figure 4) . The increase varied from 3-to 300-fold in different individuals and was significantly correlated with the quantity of antigen administered.
Parenteral immunization with pollen antigens is known to stimulate the production of "blocking antibodies" (6) , which bind antigen but do not mediate passive sensitization. A deficiency in the latter property suggests that these antibodies also have a lower affinity for the leukocyte surface than do the classic "reagins," and hence would not displace them from the cell. The relationship between our measurements of antigen-neutralizing capacity and so-called blocking antibodies is not yet clear. However, the presence in the serum of antigen neutralization activity, even at elevated levels, is compatible with the minimal changes noted in the sensitivity of the isolated leukocytes. The effect of serum antibody levels greater than those we observed remains to be explored.
The method used for estimating the antigen-neutralizing capacity in sera of allergic donors is perhaps uniquely suitable for the present study. This procedure provides a quantitative measure of the biologic activity of the antibody, i.e., its capacity to unite with antigen and inhibit the allergic response (14) . The correlation between cell sensitivity and patient symptomatology that emerged in the present investigation shows that cell sensitivity may be used as a reference against which to evaluate the clinical efficacy of any increase in antibody activity.
From the data presented above it appears likely that the goal of therapy should be to decrease the effective sensitivity of the histamine-releasing cells in their milieu of extracellular fluid. This may be achieved by at least two mechanisms. The cellular sensitivity itself, attributable to cell-bound antibodies, may be reduced. The changes that we have noted in this respect have thus far been too small to influence clinical symptoms. More intensive immunization might be more effective in altering cell sensitivity, as is suggested by the preliminary reports of others (28, 29) . The other pertinent mechanism involves increased serum antibody levels. Our data suggest that in several individuals treated with antigen E the immune response sufficed to influence the clinical course, i.e., these patients had fewer symptoms than were anticipated on the basis of their cell sensitivity. It appears likely, therefore, that some combination of cell sensitivity and antigen-neutralizing capacity is the principal determinant of clinical symptomatology in ragweed pollinosis. Summary An in vitro reaction system for the study of human allergy has been utilized to evaluate the effects of desensitization therapy in ragweed pollinosis. This system involves the antigenically induced release of histamine from isolated human leukocytes and is designed to allow an independent evaluation of cellular and humoral factors. The sensitivity of a donor's leukocytes to the offending antigen correlated significantly with the degree of symptomatology suffered by that patient during the ragweed season. The cell sensitivity was not altered by environmental exposure to this antigen or by the therapeutic regimen used in this study. The sera of all ragweed-sensitive patients, whether treated or not, contained antibodies capable of binding the antigen and thereby decreasing the in vitro allergic response. The level of antibody activity did not change in a group of patients receiving placebo immunization, but did increase in the groups treated with ragweed antigen. The extent of this response correlated well with the quantity of antigen E administered. Although there was no significant clinical difference between the groups treated with placebo and specific antigen, it appears that several individuals whose sera developed the highest levels of antiragweed activity had milder symptoms than expected on the basis of their cellular sensitivity to antigen.
